Cantor Fitzgerald Reiterates Overweight Rating for Structure Therapeutics (NASDAQ:GPCR)

Structure Therapeutics (NASDAQ:GPCR - Get Free Report)'s stock had its "overweight" rating reiterated by analysts at Cantor Fitzgerald in a report issued on Monday,Benzinga reports. They currently have a $65.00 price target on the stock. Cantor Fitzgerald's price objective would suggest a potential upside of 208.35% from the company's previous close.

Other research analysts also recently issued research reports about the stock. JMP Securities reiterated a "market outperform" rating and issued a $89.00 target price on shares of Structure Therapeutics in a report on Monday. HC Wainwright decreased their target price on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. Citigroup began coverage on Structure Therapeutics in a research report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target on the stock. Finally, William Blair assumed coverage on shares of Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $76.17.

Structure Therapeutics Stock Down 3.3%

Shares of Structure Therapeutics stock traded down $0.71 on Monday, hitting $21.08. 550,991 shares of the company traded hands, compared to its average volume of 843,884. The company has a 50-day moving average price of $23.46 and a 200 day moving average price of $24.04. Structure Therapeutics has a 12-month low of $13.22 and a 12-month high of $47.48. The company has a market cap of $1.21 billion, a PE ratio of -24.23 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Equities research analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several large investors have recently made changes to their positions in the company. Janus Henderson Group PLC grew its stake in shares of Structure Therapeutics by 5.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock worth $112,816,000 after purchasing an additional 203,010 shares during the period. Deep Track Capital LP grew its position in shares of Structure Therapeutics by 129.4% in the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock valued at $75,936,000 after purchasing an additional 1,579,492 shares during the period. Vestal Point Capital LP increased its position in shares of Structure Therapeutics by 3.7% during the first quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock worth $30,967,000 after acquiring an additional 63,990 shares in the last quarter. Capital International Investors increased its holdings in Structure Therapeutics by 6.8% during the 4th quarter. Capital International Investors now owns 1,619,081 shares of the company's stock worth $43,909,000 after purchasing an additional 103,059 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of Structure Therapeutics by 29.4% in the 4th quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock valued at $38,512,000 after purchasing an additional 322,601 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.